Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT
Identifieur interne : 007A55 ( Main/Merge ); précédent : 007A54; suivant : 007A56Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT
Auteurs : Robert B. Innis ; Kenneth L. Marek ; Kim Sheff ; Sami Zoghbi ; Joseph Castronuovo [États-Unis] ; Andrew Feigin [États-Unis] ; John P. SeibylSource :
- Movement Disorders [ 0885-3185 ] ; 1999-05.
English descriptors
- KwdEn :
Abstract
The effect of subchronic treatment with l‐dopa/carbidopa or l‐selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic Parkinson's disease with SPECT (single photon emission computed tomography) using [123I]β‐CIT (2β‐carbomethoxy‐3β‐[4‐iodophenyl]tropane) as the radiotracer. Patients who were not currently being treated with these medications were given either 750 mg l‐dopa/carbidopa per day (n = 8) or 10 mg l‐selegiline per day (n = 8). [123I]β‐CIT imaging was performed three times in each patient: at baseline before treatment, while on medication and after 4–6 weeks of drug treatment, and following withdrawal from medication (approximately 1 week for l‐dopa/carbidopa and 9 weeks for l‐selegiline). Comparison of scans 2 and 3 provided a measure of drug occupancy of the [123I]β‐CIT binding site; comparison of scans 1 and 2 provided a measure of both up‐ or downregulation of DAT levels and drug occupancy following subchronic drug treatment. DAT levels were assessed from an image acquired approximately 22 hours after radiotracer injection as a ratio of regional brain activities: (striatum − occipital)/occipital. Striatal DAT levels were not significantly different when any two of the three scans were compared for both drug treatments. These results suggest that typical clinical doses of l‐dopa/carbidopa and l‐selegiline do not induce significant occupancy of the [123I]β‐CIT binding site and that 4–6 weeks of treatment causes no significant modulation of DAT levels. These results support the validity of measuring DAT levels with [123I]β‐CIT without the need to withdraw patients from medication treatment.
Url:
DOI: 10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000831
- to stream Istex, to step Curation: 000831
- to stream Istex, to step Checkpoint: 003523
Links to Exploration step
ISTEX:3A960777901D76285C804BFDFDC9C22BA1D38C9CLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT</title><author><name sortKey="Innis, Robert B" sort="Innis, Robert B" uniqKey="Innis R" first="Robert B." last="Innis">Robert B. Innis</name></author><author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name></author><author><name sortKey="Sheff, Kim" sort="Sheff, Kim" uniqKey="Sheff K" first="Kim" last="Sheff">Kim Sheff</name></author><author><name sortKey="Zoghbi, Sami" sort="Zoghbi, Sami" uniqKey="Zoghbi S" first="Sami" last="Zoghbi">Sami Zoghbi</name></author><author><name sortKey="Castronuovo, Joseph" sort="Castronuovo, Joseph" uniqKey="Castronuovo J" first="Joseph" last="Castronuovo">Joseph Castronuovo</name></author><author><name sortKey="Feigin, Andrew" sort="Feigin, Andrew" uniqKey="Feigin A" first="Andrew" last="Feigin">Andrew Feigin</name></author><author><name sortKey="Seibyl, John P" sort="Seibyl, John P" uniqKey="Seibyl J" first="John P." last="Seibyl">John P. Seibyl</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:3A960777901D76285C804BFDFDC9C22BA1D38C9C</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J</idno><idno type="url">https://api.istex.fr/document/3A960777901D76285C804BFDFDC9C22BA1D38C9C/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000831</idno><idno type="wicri:Area/Istex/Curation">000831</idno><idno type="wicri:Area/Istex/Checkpoint">003523</idno><idno type="wicri:doubleKey">0885-3185:1999:Innis R:effect:of:treatment</idno><idno type="wicri:Area/Main/Merge">007A55</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT</title><author><name sortKey="Innis, Robert B" sort="Innis, Robert B" uniqKey="Innis R" first="Robert B." last="Innis">Robert B. Innis</name><affiliation><wicri:noCountry code="subField">Yale University School of Medicine</wicri:noCountry></affiliation><affiliation><wicri:noCountry code="no comma">VA Connecticut at West Haven</wicri:noCountry></affiliation></author><author><name sortKey="Marek, Kenneth L" sort="Marek, Kenneth L" uniqKey="Marek K" first="Kenneth L." last="Marek">Kenneth L. Marek</name><affiliation><wicri:noCountry code="subField">Yale University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Sheff, Kim" sort="Sheff, Kim" uniqKey="Sheff K" first="Kim" last="Sheff">Kim Sheff</name><affiliation><wicri:noCountry code="subField">Yale University School of Medicine</wicri:noCountry></affiliation><affiliation><wicri:noCountry code="no comma">VA Connecticut at West Haven</wicri:noCountry></affiliation></author><author><name sortKey="Zoghbi, Sami" sort="Zoghbi, Sami" uniqKey="Zoghbi S" first="Sami" last="Zoghbi">Sami Zoghbi</name><affiliation><wicri:noCountry code="subField">Yale University School of Medicine</wicri:noCountry></affiliation></author><author><name sortKey="Castronuovo, Joseph" sort="Castronuovo, Joseph" uniqKey="Castronuovo J" first="Joseph" last="Castronuovo">Joseph Castronuovo</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Nuclear Medicine, North Shore University Hospital, Manhasset and Glen Cove, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Feigin, Andrew" sort="Feigin, Andrew" uniqKey="Feigin A" first="Andrew" last="Feigin">Andrew Feigin</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Departments of Neurology and Nuclear Medicine, North Shore University Hospital, Manhasset and Glen Cove, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Seibyl, John P" sort="Seibyl, John P" uniqKey="Seibyl J" first="John P." last="Seibyl">John P. Seibyl</name><affiliation><wicri:noCountry code="subField">Yale University School of Medicine</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="1999-05">1999-05</date><biblScope unit="vol">14</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="436">436</biblScope><biblScope unit="page" to="442">442</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">3A960777901D76285C804BFDFDC9C22BA1D38C9C</idno><idno type="DOI">10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J</idno><idno type="ArticleID">MDS1008</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine transporter</term><term>Parkinson's disease</term><term>SPECT</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The effect of subchronic treatment with l‐dopa/carbidopa or l‐selegiline on striatal dopamine transporters (DAT) was examined in patients with idiopathic Parkinson's disease with SPECT (single photon emission computed tomography) using [123I]β‐CIT (2β‐carbomethoxy‐3β‐[4‐iodophenyl]tropane) as the radiotracer. Patients who were not currently being treated with these medications were given either 750 mg l‐dopa/carbidopa per day (n = 8) or 10 mg l‐selegiline per day (n = 8). [123I]β‐CIT imaging was performed three times in each patient: at baseline before treatment, while on medication and after 4–6 weeks of drug treatment, and following withdrawal from medication (approximately 1 week for l‐dopa/carbidopa and 9 weeks for l‐selegiline). Comparison of scans 2 and 3 provided a measure of drug occupancy of the [123I]β‐CIT binding site; comparison of scans 1 and 2 provided a measure of both up‐ or downregulation of DAT levels and drug occupancy following subchronic drug treatment. DAT levels were assessed from an image acquired approximately 22 hours after radiotracer injection as a ratio of regional brain activities: (striatum − occipital)/occipital. Striatal DAT levels were not significantly different when any two of the three scans were compared for both drug treatments. These results suggest that typical clinical doses of l‐dopa/carbidopa and l‐selegiline do not induce significant occupancy of the [123I]β‐CIT binding site and that 4–6 weeks of treatment causes no significant modulation of DAT levels. These results support the validity of measuring DAT levels with [123I]β‐CIT without the need to withdraw patients from medication treatment.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007A55 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 007A55 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:3A960777901D76285C804BFDFDC9C22BA1D38C9C
|texte= Effect of treatment with L‐dopa/carbidopa or L‐selegiline on striatal dopamine transporter SPECT imaging with [123I]β‐CIT
}}
| This area was generated with Dilib version V0.6.23. |  |